AKBLF Quote, Financials, Valuation and Earnings

Bavarian Nordic A/S has a net margin of 15.35% compared to ALK-Abello A/S's net margin of 62.31%. ALK-Abello A/S's return on equity of 20.18% beat Bavarian Nordic A/S's return on equity of 20.81%.

ALK-Abello A/S has a consensus price target of --, signalling downside risk potential of --. On the other hand Bavarian Nordic A/S has an analysts' consensus of -- which suggests that it could fall by --. Given that ALK-Abello A/S has higher upside potential than Bavarian Nordic A/S, analysts believe ALK-Abello A/S is more attractive than Bavarian Nordic A/S.

ALK-Abello A/S has a beta of 0.699, which suggesting that the stock is 30.054% less volatile than S&P 500. In comparison Bavarian Nordic A/S has a beta of 1.360, suggesting its more volatile than the S&P 500 by 35.968%.

ALK-Abello A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bavarian Nordic A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ALK-Abello A/S pays -- of its earnings as a dividend. Bavarian Nordic A/S pays out -- of its earnings as a dividend.

ALK-Abello A/S quarterly revenues are $270.1M, which are smaller than Bavarian Nordic A/S quarterly revenues of $274.6M. ALK-Abello A/S's net income of $41.5M is lower than Bavarian Nordic A/S's net income of $171.1M. Notably, ALK-Abello A/S's price-to-earnings ratio is 43.93x while Bavarian Nordic A/S's PE ratio is 6.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ALK-Abello A/S is 8.29x versus 2.38x for Bavarian Nordic A/S. Usually stocks with elevated PS ratios are considered overvalued.

Evaxion AS has a net margin of 15.35% compared to ALK-Abello A/S's net margin of -64.14%. ALK-Abello A/S's return on equity of 20.18% beat Evaxion AS's return on equity of --.

ALK-Abello A/S has a consensus price target of --, signalling downside risk potential of --. On the other hand Evaxion AS has an analysts' consensus of $11.75 which suggests that it could grow by 257.14%. Given that Evaxion AS has higher upside potential than ALK-Abello A/S, analysts believe Evaxion AS is more attractive than ALK-Abello A/S.

ALK-Abello A/S has a beta of 0.699, which suggesting that the stock is 30.054% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

ALK-Abello A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ALK-Abello A/S pays -- of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend.

ALK-Abello A/S quarterly revenues are $270.1M, which are larger than Evaxion AS quarterly revenues of $37.5K. ALK-Abello A/S's net income of $41.5M is higher than Evaxion AS's net income of -$4.9M. Notably, ALK-Abello A/S's price-to-earnings ratio is 43.93x while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ALK-Abello A/S is 8.29x versus 2.21x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

Genmab A/S has a net margin of 15.35% compared to ALK-Abello A/S's net margin of 2.93%. ALK-Abello A/S's return on equity of 20.18% beat Genmab A/S's return on equity of 17.69%.

ALK-Abello A/S has a consensus price target of --, signalling downside risk potential of --. On the other hand Genmab A/S has an analysts' consensus of $37.94 which suggests that it could grow by 29.55%. Given that Genmab A/S has higher upside potential than ALK-Abello A/S, analysts believe Genmab A/S is more attractive than ALK-Abello A/S.

ALK-Abello A/S has a beta of 0.699, which suggesting that the stock is 30.054% less volatile than S&P 500. In comparison Genmab A/S has a beta of 0.899, suggesting its less volatile than the S&P 500 by 10.054%.

ALK-Abello A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genmab A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ALK-Abello A/S pays -- of its earnings as a dividend. Genmab A/S pays out -- of its earnings as a dividend.

ALK-Abello A/S quarterly revenues are $270.1M, which are smaller than Genmab A/S quarterly revenues of $1.1B. ALK-Abello A/S's net income of $41.5M is higher than Genmab A/S's net income of $31M. Notably, ALK-Abello A/S's price-to-earnings ratio is 43.93x while Genmab A/S's PE ratio is 18.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ALK-Abello A/S is 8.29x versus 5.00x for Genmab A/S. Usually stocks with elevated PS ratios are considered overvalued.

Zealand Pharma A/S has a net margin of 15.35% compared to ALK-Abello A/S's net margin of -550.12%. ALK-Abello A/S's return on equity of 20.18% beat Zealand Pharma A/S's return on equity of 51.22%.

ALK-Abello A/S has a consensus price target of --, signalling downside risk potential of --. On the other hand Zealand Pharma A/S has an analysts' consensus of -- which suggests that it could fall by -62.76%. Given that Zealand Pharma A/S has higher upside potential than ALK-Abello A/S, analysts believe Zealand Pharma A/S is more attractive than ALK-Abello A/S.

ALK-Abello A/S has a beta of 0.699, which suggesting that the stock is 30.054% less volatile than S&P 500. In comparison Zealand Pharma A/S has a beta of 0.725, suggesting its less volatile than the S&P 500 by 27.461%.

ALK-Abello A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zealand Pharma A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ALK-Abello A/S pays -- of its earnings as a dividend. Zealand Pharma A/S pays out -- of its earnings as a dividend.

ALK-Abello A/S quarterly revenues are $270.1M, which are larger than Zealand Pharma A/S quarterly revenues of $10.7M. ALK-Abello A/S's net income of $41.5M is higher than Zealand Pharma A/S's net income of -$59.1M. Notably, ALK-Abello A/S's price-to-earnings ratio is 43.93x while Zealand Pharma A/S's PE ratio is 4.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ALK-Abello A/S is 8.29x versus 3.06x for Zealand Pharma A/S. Usually stocks with elevated PS ratios are considered overvalued.